Abstract 3219
Background
Individuals newly diagnosed with cancer may experience impairments in several aspects of health and often have a high need for both information and support. Approximately 30 % will experience symptoms of anxiety and depression with varying needs of support. E-health interventions such as internet-based interactive health communication applications (IHCAs) may offer a supplement to standard care services. Developers of such interventions need to work closely with presumptive users to add relevance and value. The purpose was to explore the user experiences of an IHCA targeting individuals with breast- colorectal or prostate cancer with symptoms of anxiety and depression.
Methods
A qualitative study with inductive approach was conducted, where 15 individuals using an IHCA targeting symptoms of anxiety and depression were interviewed with semi-structured questions. Content analysis was used to analyze interviews.
Results
The need for information was described as high, and almost looked upon as a survival strategy when newly diagnosed. The IHCA was experienced as a useful, reliable source of information and support, and was used as a complement to standard care. Increased knowledge was a foundation for continued processing of own feelings and the favorable time to get access to the IHCA was when being informed of the diagnose. The common denominator was that of being acknowledged but with a further desire for individual adjustment to own situation and needs.
Conclusions
The IHCA was experienced as a safe and reliable complement to standard care. Similar interventions may gain from a more individualized content, being integrated in to standard care and/or by using tracking of symptoms to adjust the content. Offering the IHCA closer to diagnosis may provide more benefits to users.
Clinical trial identification
NCT-01630681.
Editorial acknowledgement
Legal entity responsible for the study
Regional Committee for Research Ethics Sweden, Uppsala county (Dnr 2012/003/9).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract